X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (34) 34
female (31) 31
index medicus (30) 30
oncology (30) 30
male (29) 29
aged (26) 26
middle aged (25) 25
cancer (19) 19
carcinoma, non-small-cell lung - drug therapy (19) 19
lung neoplasms - drug therapy (19) 19
adult (16) 16
carcinoma, non-small-cell lung - pathology (15) 15
chemotherapy (15) 15
life sciences (15) 15
lung cancer (14) 14
lung neoplasms - pathology (14) 14
respiratory system (14) 14
aged, 80 and over (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
treatment outcome (10) 10
neoplasm staging (9) 9
therapy (9) 9
carboplatin (8) 8
survival rate (8) 8
care and treatment (7) 7
hematology, oncology and palliative medicine (7) 7
lung cancer, non-small cell (7) 7
trial (7) 7
young adult (7) 7
antineoplastic agents (6) 6
bevacizumab (6) 6
carcinoma, non-small-cell lung - mortality (6) 6
lung neoplasms - mortality (6) 6
prognosis (6) 6
research (6) 6
tumors (6) 6
antimitotic agents (5) 5
antineoplastic agents - therapeutic use (5) 5
cell lung-cancer (5) 5
ceritinib (5) 5
cisplatin - administration & dosage (5) 5
clinical trials (5) 5
deoxycytidine - administration & dosage (5) 5
deoxycytidine - analogs & derivatives (5) 5
kaplan-meier estimate (5) 5
lung neoplasms - genetics (5) 5
mutation (5) 5
prospective studies (5) 5
protein kinase inhibitors - therapeutic use (5) 5
pulmonary/respiratory (5) 5
retrospective studies (5) 5
safety (5) 5
survival (5) 5
time factors (5) 5
vinblastine - administration & dosage (5) 5
vinblastine - analogs & derivatives (5) 5
[ sdv.can ] life sciences [q-bio]/cancer (4) 4
[sdv.can]life sciences [q-bio]/cancer (4) 4
administration, oral (4) 4
alectinib (4) 4
angiogenesis inhibitors - administration & dosage (4) 4
angiogenesis inhibitors - adverse effects (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
cancer therapies (4) 4
carboplatin - administration & dosage (4) 4
carcinoma (4) 4
carcinoma, non-small-cell lung - radiotherapy (4) 4
cisplatin (4) 4
classification (4) 4
combination (4) 4
crizotinib (4) 4
disease-free survival (4) 4
docetaxel (4) 4
france (4) 4
neoplasms. tumors. oncology. including cancer and carcinogens (4) 4
oncology, experimental (4) 4
open-label (4) 4
paclitaxel (4) 4
paclitaxel - administration & dosage (4) 4
radiation (4) 4
radiation therapy (4) 4
resistance (4) 4
risk factors (4) 4
survival analysis (4) 4
thymic carcinoma (4) 4
thymoma (4) 4
toxicity (4) 4
adenocarcinoma - drug therapy (3) 3
adolescent (3) 3
alk (3) 3
analysis (3) 3
angiogenesis inhibitors - therapeutic use (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic combined chemotherapy protocols (3) 3
brain neoplasms - drug therapy (3) 3
brain neoplasms - secondary (3) 3
carcinoma, non-small-cell lung - genetics (3) 3
cohort studies (3) 3
diagnosis (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9796, pp. 1079 - 1088
Summary Background Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell lung cancer (NSCLC) in fit, non-elderly adults, but... 
Internal Medicine | SURVIVAL | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | INTERNATIONAL-SOCIETY | GERIATRIC ASSESSMENT | UNDERREPRESENTATION | OLDER | OUTCOMES | COMBINATION | AGE | COMORBIDITY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Vinblastine - administration & dosage | Carboplatin - adverse effects | Carcinoma, Squamous Cell - mortality | Vinblastine - analogs & derivatives | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Paclitaxel - administration & dosage | Drug Administration Schedule | Deoxycytidine - administration & dosage | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Survival Rate | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Clinical trials | Chemotherapy | Radiation therapy | Cancer therapies | Adenocarcinoma | Vinblastine | Carcinoma, Non-Small-Cell Lung | Antineoplastic Agents | Antineoplastic Combined Chemotherapy Protocols | Lung Neoplasms | Carcinoma, Squamous Cell | Life Sciences | Deoxycytidine | Paclitaxel | Carboplatin | Cancer
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 16, pp. 1997 - 2003
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
The European respiratory journal, ISSN 0903-1936, 10/2017, Volume 50, Issue 4, pp. 1700716 - 1700716
Journal Article
Journal Article
BMC Cancer, ISSN 1471-2407, 03/2014, Volume 14, Issue 1, p. 231
Journal Article
BMC Cancer, ISSN 1471-2407, 07/2018, Volume 18, Issue 1
The primary aim of this trial was to determine the recommended phase II dose (RP2D) of weekly paclitaxel (wP) administered in combination with oral metronomic... 
Clinical trials | Cyclophosphamide | Dosage and administration | Analysis | Paclitaxel
Journal Article
Lung Cancer, ISSN 0169-5002, 11/2016, Volume 101, p. 146
The publisher regrets the incorrect spelling of Co-Author's name Laurent Greillier. This was incorrectly published online and in print as Laurent Grellier. The... 
Journal Article
Lung Cancer, ISSN 0169-5002, 2016, Volume 97, pp. 99 - 104
Journal Article
Journal Article